---
title: "Galectin Therapeutics Inc. (GALT.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/GALT.US.md"
symbol: "GALT.US"
name: "Galectin Therapeutics Inc."
industry: "Biotechnology"
---

# Galectin Therapeutics Inc. (GALT.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [galectintherapeutics.com](https://galectintherapeutics.com) |

## Company Profile

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -5.05 | 373/604 | - | - | - |
| PB | -1.50 | 490/604 | - | - | - |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-12-19T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.99 |
| Highest Target | 11.00 |
| Lowest Target | 11.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/GALT.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/GALT.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/GALT.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.